Drug Trial Radar · NCT02323659
Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous T-cell Lymphomas
Last checked: Nov 20, 2026Latest source record: Jan 13, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
100
Planned (sponsor's estimate)
Start
Jun 1, 2014
Primary completion
Mar 2018
Study completion Mar 31, 2018
Sponsor
- Lead sponsor
- Polish Lymphoma Research GroupResearch network
- Sponsor type
- Research network
- First posted
- Dec 23, 2014
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Comparison of methotrexate versus interferon-alfa 2b on efficacy, safety and quality of life in patients with primary cutaneous T-cell lymphomas after failure of topical or phototherapy treatment.
Conditions
- Lymphoma, T-Cell, Cutaneous
- Mycosis Fungoides
Interventions
MethotrexateDrug
Methotrexate 20mg per dose, administered orally, once every week
Interferon Alfa-2bDrug
Interferon Alfa-2b 3 million international units (MIU), administered 3 times per week
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rate as measured by the modified Severity Weighted Assessment Tool (mSWAT scoring system)Time frame: 3 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Centrum Onkologii im. prof. F. Łukaszczyka
Bydgoszcz, Poland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.